The current financial score of Cytek Biosciences Inc is 7.44. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 48.14M, representing a year-over-year increase of 5.57%, while its net profit experienced a year-over-year increase of 117.77%.
The current valuation score of Cytek Biosciences Inc is 8.61. Its current P/E ratio is -9.16, which is -7779.06% below the recent high of 703.39 and -92275.88% above the recent low of -8461.54.
The current earnings forecast score of Cytek Biosciences Inc is 7.50. The average price target is 5.56, with a high of 7.50 and a low of 4.75.
The current price momentum score of Cytek Biosciences Inc is 5.56. Currently, the stock price is trading between the resistance level at 5.65 and the support level at 4.62, making it suitable for range-bound swing trading.
The current institutional shareholding score of Cytek Biosciences Inc is 5.00. The latest institutional shareholding proportion is 65.16%, representing a quarter-over-quarter decrease of 8.01%. The largest institutional shareholder is Chuck Royce, holding a total of 2.08M shares, representing 0.07% of shares outstanding, with 201.95% increase in holdings.
The current risk assessment score of Cytek Biosciences Inc is 5.28. The company's beta value is 1.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.